BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20455891)

  • 1. Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study.
    Glass LC; Cusi K; Berria R; Petz R; Cersosimo E; Defronzo RA; Gastaldelli A
    Clin Endocrinol (Oxf); 2010 Sep; 73(3):339-45. PubMed ID: 20455891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
    Bajaj M; Suraamornkul S; Pratipanawatr T; Hardies LJ; Pratipanawatr W; Glass L; Cersosimo E; Miyazaki Y; DeFronzo RA
    Diabetes; 2003 Jun; 52(6):1364-70. PubMed ID: 12765945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.
    Gastaldelli A; Casolaro A; Pettiti M; Nannipieri M; Ciociaro D; Frascerra S; Buzzigoli E; Baldi S; Mari A; Ferrannini E
    Clin Pharmacol Ther; 2007 Feb; 81(2):205-12. PubMed ID: 17259945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
    Ravikumar B; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabetes; 2008 Sep; 57(9):2288-95. PubMed ID: 18535187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
    Miyazaki Y; Matsuda M; DeFronzo RA
    Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
    Miyazaki Y; Glass L; Triplitt C; Matsuda M; Cusi K; Mahankali A; Mahankali S; Mandarino LJ; DeFronzo RA
    Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose.
    Abdul-Ghani MA; Williams K; DeFronzo R; Stern M
    Diabetes Care; 2006 Jul; 29(7):1613-8. PubMed ID: 16801587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone ameliorates endothelial dysfunction in those with impaired glucose regulation among the first-degree relatives of type 2 diabetes mellitus patients.
    Yu X; Chen P; Wang H; Zhu T
    Med Princ Pract; 2013; 22(2):156-60. PubMed ID: 22964975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of insulin release and insulin sensitivity through oral glucose tolerance test: differences between NGT, IFG, IGT, and type 2 diabetes mellitus. A cross-sectional and follow-up study.
    Pontiroli AE; Pizzocri P; Caumo A; Perseghin G; Luzi L
    Acta Diabetol; 2004 Jun; 41(2):70-6. PubMed ID: 15224208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
    Gastaldelli A; Harrison SA; Belfort-Aguilar R; Hardies LJ; Balas B; Schenker S; Cusi K
    Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of pioglitazone on the liver: role of adiponectin.
    Gastaldelli A; Miyazaki Y; Mahankali A; Berria R; Pettiti M; Buzzigoli E; Ferrannini E; DeFronzo RA
    Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazone.
    DeFronzo RA; Tripathy D; Abdul-Ghani M; Musi N; Gastaldelli A
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3774-81. PubMed ID: 24937535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.
    Cersosimo E; Gastaldelli A; Cervera A; Wajcberg E; Sriwijilkamol A; Fernandez M; Zuo P; Petz R; Triplitt C; Musi N; DeFronzo RA
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1763-70. PubMed ID: 21411546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S.
    Jensen CC; Cnop M; Hull RL; Fujimoto WY; Kahn SE;
    Diabetes; 2002 Jul; 51(7):2170-8. PubMed ID: 12086947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour?
    Radziuk J; Pye S
    Diabetologia; 2006 Jul; 49(7):1619-28. PubMed ID: 16752180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.